Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
AVXL

AVXL - Anavex Life Sciences Corp Stock Price, Fair Value and News

4.93USD-0.08 (-1.60%)Market Closed
Watchlist

Market Summary

USD4.93-0.08
Market Closed
-1.60%

AVXL Stock Price

View Fullscreen

AVXL RSI Chart

AVXL Valuation

Market Cap

404.8M

Price/Earnings (Trailing)

-9.38

Price/Sales (Trailing)

16.2K

EV/EBITDA

-7.15

Price/Free Cashflow

-13.81

AVXL Price/Sales (Trailing)

AVXL Profitability

EBT Margin

-172172.94%

Return on Equity

-31.83%

Return on Assets

-29.15%

Free Cashflow Yield

-7.24%

AVXL Fundamentals

AVXL Revenue

Revenue (TTM)

25.0K

AVXL Earnings

Earnings (TTM)

-43.2M

Earnings Growth (Yr)

33.53%

Earnings Growth (Qtr)

15.02%

Breaking Down AVXL Revenue

Last 7 days

-1.9%

Last 30 days

-5.3%

Last 90 days

-9.6%

Trailing 12 Months

-46.2%

How does AVXL drawdown profile look like?

AVXL Financial Health

Current Ratio

3.33

Debt/Equity

3e-6

Debt/Cashflow

-85.0K

AVXL Investor Care

Shares Dilution (1Y)

5.23%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202310.5M5.3M25.0K0
202250.0M35.5M21.0M15.7M
202131.6M55.3M79.1M64.6M
20203.0M3.7M7.5M7.8M
20192.8M1.7M2.5M3.0M
20181.8M1.7M1.6M2.2M
20171.3M1.7M2.0M1.9M
201600571.1K934.0K
20150000
20140000
2013131.3K129.2K176.3K182.6K
2012165.4K150.6K142.9K139.2K
201191.1K124.7K158.2K180.0K
20100024.1K57.6K

Tracking the Latest Insider Buys and Sells of Anavex Life Sciences Corp

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 29, 2023
missling christopher u
acquired
371,200
1.6
232,000
president and ceo
Jun 28, 2023
missling christopher u
sold
-2,139,310
7.9825
-268,000
president and ceo
Jun 28, 2023
missling christopher u
acquired
428,800
1.6
268,000
president and ceo
May 25, 2022
skarpelos athanasios
sold
-453,000
9.06
-50,000
-
May 25, 2022
skarpelos athanasios
acquired
46,000
0.92
50,000
-
Jun 29, 2021
missling christopher u
sold
-1,342,120
26.00
-51,620
president and ceo
Jun 29, 2021
missling christopher u
acquired
68,138
1.32
51,620
president and ceo
Jun 29, 2021
boenisch sandra
acquired
699,163
4.19424
166,696
pfo and treasurer
Jun 29, 2021
boenisch sandra
sold
-4,422,440
26.53
-166,696
pfo and treasurer
May 21, 2021
favus elliot
acquired
280,820
1.93669
145,000
-

1–10 of 15

Which funds bought or sold AVXL recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
2.66
149,000
474,000
-%
Feb 16, 2024
HARBOUR INVESTMENTS, INC.
added
67.00
4,499
7,774
-%
Feb 15, 2024
Farther Finance Advisors, LLC
new
-
410
410
-%
Feb 15, 2024
JANE STREET GROUP, LLC
added
36.55
506,862
1,045,610
-%
Feb 15, 2024
Legal & General Group Plc
reduced
-0.28
195,397
663,552
-%
Feb 15, 2024
BARCLAYS PLC
added
31.05
907,000
1,959,000
-%
Feb 14, 2024
MetLife Investment Management, LLC
unchanged
-
100,047
337,478
-%
Feb 14, 2024
D. E. Shaw & Co., Inc.
added
64.27
284,513
497,657
-%
Feb 14, 2024
AQR CAPITAL MANAGEMENT LLC
added
10.77
63,187
173,175
-%
Feb 14, 2024
AMUNDI
new
-
21,409
21,409
-%

1–10 of 39

Are Funds Buying or Selling AVXL?

Are funds buying AVXL calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AVXL
No. of Funds

Unveiling Anavex Life Sciences Corp's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
5.31%
4,360,648
SC 13G/A
Jan 25, 2024
blackrock inc.
8.1%
6,671,075
SC 13G/A
Jan 22, 2024
state street corp
4.44%
3,642,702
SC 13G/A
Feb 09, 2023
vanguard group inc
5.32%
4,144,500
SC 13G/A
Feb 09, 2023
state street corp
7.46%
5,812,605
SC 13G/A
Jan 31, 2023
blackrock inc.
7.2%
5,578,159
SC 13G/A
Feb 09, 2022
state street corp
5.04%
3,834,034
SC 13G
Feb 09, 2022
vanguard group inc
5.05%
3,841,570
SC 13G
Feb 03, 2022
blackrock inc.
6.9%
5,262,666
SC 13G/A
Feb 16, 2021
park west asset management llc
0.0%
0
SC 13G/A

Recent SEC filings of Anavex Life Sciences Corp

View All Filings
Date Filed Form Type Document
Feb 23, 2024
4
Insider Trading
Feb 23, 2024
4
Insider Trading
Feb 23, 2024
4
Insider Trading
Feb 23, 2024
4
Insider Trading
Feb 23, 2024
4
Insider Trading
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 07, 2024
10-Q
Quarterly Report
Jan 25, 2024
SC 13G/A
Major Ownership Report
Jan 22, 2024
SC 13G/A
Major Ownership Report
Jan 12, 2024
4
Insider Trading

Peers (Alternatives to Anavex Life Sciences Corp)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
36.8B
6.8B
-16.59% -47.80%
-7.82
5.38
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.9B
1.8B
-23.99% -31.71%
-45.13
10.87
76.23% 61.08%
17.2B
2.3B
-4.89% -18.90%
116.89
7.44
15.05% 75.21%
13.6B
3.7B
-7.62% -26.87%
22.76
3.68
8.87% 75.42%
MID-CAP
8.1B
272.9M
-2.06% 34.31%
-13.4
29.75
141.38% 4.43%
6.0B
-
-3.85% 226.12%
-9.54
60.35
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.34
6.44
23.54% 31.53%
3.9B
240.7M
-19.08% -10.99%
-13.19
16.26
-1.03% -92.09%
3.7B
270.6M
8.92% 47.81%
-15.63
13.81
440.80% -27.84%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
24.15
4.3
81.69% -7.29%
629.6M
1.0B
-9.17% -57.89%
-1.15
0.6
-43.15% 58.48%
179.0M
4.9M
-14.18% -58.18%
-1.09
36.62
-57.57% 50.48%
114.7M
881.7K
289.54% 381.25%
-2.42
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Anavex Life Sciences Corp News

Latest updates
AmericanBankingNEWS38 hours ago
The Washington Post07 Feb 202408:00 am
Quartz07 Feb 202408:00 am

Anavex Life Sciences Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue-------------1,269,3164,519,4441,319,913717,328943,215738,684552,335760,990413,682
Operating Expenses-10.7%11,293,00012,652,18913,530,69714,189,15915,383,95515,284,14312,458,72011,519,74711,723,39012,252,58411,398,6558,954,5869,396,175-54,668,6038,106,4797,773,1897,700,7036,346,2197,147,1758,140,0377,473,517
  S&GA Expenses0.7%2,609,0002,591,5533,247,8432,882,5683,317,0363,902,4403,185,4512,915,1583,066,9512,879,4722,434,1272,233,7451,470,6561,402,9551,381,4771,720,1421,352,0351,635,3121,388,7292,061,2511,761,307
  R&D Expenses-13.7%8,684,00010,060,63610,282,85411,306,59112,066,91911,381,7039,273,2698,604,5898,656,4399,373,1128,964,5286,720,8417,925,5196,104,9066,725,0026,053,0476,348,6684,710,9075,758,4466,078,7865,712,210
EBITDA Margin10.9%-1,460-1,639-8.76-4.64-3.02-2.22-1.26-0.86-0.63-0.48-0.58-0.90---------
Interest Expenses-100.0%-1,958,2161,827,9451,465,2211,267,618704,595229,9177,5784,9106,89011,4539,216-1,5596,97756,09670,18046,72042,17734,83851,46578,800
Income Taxes232.9%85,000-63,95441,00050,000-20,046209,79988,42129,80029,980142,73139,00026,98859,2818,6334,817-9,2146,11619,30048,0488,717
Earnings Before Taxes16.4%-8,537,000-10,209,981-11,238,976-13,057,279-12,991,764-14,080,682-12,278,920-10,408,011-10,852,387-11,575,841-10,141,141-8,128,234-7,795,784-5,956,593-6,481,805-7,236,697-6,582,711-5,600,302-6,502,626-7,198,856-6,911,014
EBT Margin9.4%-1,721-1,899-9.76-4.99-3.16-2.27-1.27-0.86-0.63-0.48-0.58-0.90---------
Net Income15.0%-8,622,000-10,146,027-11,279,976-13,107,279-12,971,718-14,290,481-12,367,341-10,437,811-10,882,367-11,718,572-10,180,141-8,155,222-7,855,065-5,965,226-6,486,622-7,236,697-6,591,925-5,606,418-6,521,926-7,246,904-6,919,731
Net Income Margin9.2%-1,726-1,900-9.81-5.02-3.18-2.29-1.28-0.86-0.63-0.48-0.58-0.90---------
Free Cashflow-25.1%-7,318,000-5,849,629-7,652,535-8,488,579-5,794,257-4,044,071-7,053,490-9,639,484-3,500,955-7,674,834-7,520,943-7,316,845---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-4.1%14815415815914815316016015716216684.0054.0035.0032.0031.0031.0025.0022.0021.0022.00
  Current Assets---------------32.00--25.0022.0021.0022.00
    Cash Equivalents-4.8%14415115515314414915315315115215876.0047.0029.0028.0027.0027.0022.0021.0019.0021.00
Liabilities-0.3%12.0013.0011.0014.0013.0010.0010.0011.0011.0011.009.009.008.007.007.006.006.005.00---
  Current Liabilities-------9.008.0011.0011.00-8.008.007.007.006.005.005.004.006.005.00
Shareholder's Equity-4.4%13614214714513514215115214615115776.0046.0027.0025.0025.0026.0020.0021.0017.0019.00
  Retained Earnings-2.9%-301-293-282-271-258-245-231-218-208-197-185-175-167-159-153-147-139-133-131-124-116
  Additional Paid-In Capital0.5%437435430417394388382371355348343251214187178172166154149139133
Shares Outstanding0.0%82.0082.0081.0080.0078.0078.0078.0077.0076.0070.0075.0070.00---------
Float----667---921---1,012---177---140-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-25.1%-7,318-5,849-7,652-8,488-5,794-4,044-7,053-9,639-3,500-7,674-7,520-7,316-7,871-6,254-4,044-5,262-5,725-2,534-7,501-4,331-4,160
  Share Based Compensation-28.3%2,2863,1873,8673,9705,3476,0423,9894,4393,9093,1522,2941,8469396611,2511,7011,2641,2371,2341,8932,067
Cashflow From Financing-97.1%59.002,0569,00318,3342582.006,91011,8362,5402,22389,22235,81925,9807,8855,1004,36810,9983,4719,2933,0741,945
  Buy Backs-100.0%-1,1888,53518,153-----------------

AVXL Income Statement

2023-12-31
Condensed Consolidated Interim Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Operating expenses  
General and administrative$ 2,609$ 3,317
Research and development8,68412,067
Total operating expenses11,29315,384
Operating loss(11,293)(15,384)
Other income  
Grant income25
Research and development incentive income592733
Interest income, net2,0081,268
Foreign exchange gain156366
Total other income, net2,7562,392
Net loss before provision for income taxes(8,537)(12,992)
Income tax recovery (expense), current(85)20
Net loss and comprehensive loss$ (8,622)$ (12,972)

AVXL Balance Sheet

2023-12-31
Condensed Consolidated Interim Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Sep. 30, 2023
Current  
Cash and cash equivalents$ 143,765$ 151,024
Incentive and tax receivables3,5492,709
Prepaid expenses and other current assets756653
Total Assets148,070154,386
Current Liabilities  
Accounts payable4,2924,322
Accrued liabilities - Note 47,2867,295
Deferred grant income - Note 3917917
Total Liabilities12,49512,534
Commitments and Contingencies - Note 6
Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share
Capital stock Authorized:200,000,000 common stock, par value $0.001 per share 82,086,511 common shares (September 30, 2023 - 82,066,511)8282
Additional paid-in capital437,184434,839
Accumulated deficit(301,691)(293,069)
Total Stockholders' Equity135,575141,852
 Total Liabilities and Stockholders' Equity$ 148,070$ 154,386
AVXL
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
 CEO
 WEBSITEwww.anavex.com
 EMPLOYEES38

Anavex Life Sciences Corp Frequently Asked Questions


What is the ticker symbol for Anavex Life Sciences Corp? What does AVXL stand for in stocks?

AVXL is the stock ticker symbol of Anavex Life Sciences Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Anavex Life Sciences Corp (AVXL)?

As of Fri Feb 23 2024, market cap of Anavex Life Sciences Corp is 404.81 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AVXL stock?

You can check AVXL's fair value in chart for subscribers.

What is the fair value of AVXL stock?

You can check AVXL's fair value in chart for subscribers. The fair value of Anavex Life Sciences Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Anavex Life Sciences Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AVXL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Anavex Life Sciences Corp a good stock to buy?

The fair value guage provides a quick view whether AVXL is over valued or under valued. Whether Anavex Life Sciences Corp is cheap or expensive depends on the assumptions which impact Anavex Life Sciences Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AVXL.

What is Anavex Life Sciences Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Feb 23 2024, AVXL's PE ratio (Price to Earnings) is -9.38 and Price to Sales (PS) ratio is 16.19 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AVXL PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Anavex Life Sciences Corp's stock?

In the past 10 years, Anavex Life Sciences Corp has provided 0.338 (multiply by 100 for percentage) rate of return.